medRxiv preprint doi: https://doi.org/10.1101/2024.01.28.24301904; this version posted January 30, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

- Article 1
- 2

Serological Survey in a university community after the fourth 3 wave of COVID-19 in Senegal 4

5

Fatou THIAM 1*, Abou Abdallah Malick DIOUARA 1, Clemence Stephanie Chloe Anoumba 6 NDIAYE¹, Ibrahima DIOUF², Khadim KEBE¹, Assane SENGHOR¹, Djibaba DJOUMOI¹, 7 Mame Ndew MBAYE¹, Idy DIOP³, Sarbanding SANE¹, Seynabou COUNDOUL¹, Sophie deli 8 9 TENE¹, Mamadou DIOP¹, Abdou Lahat DIENG², Mamadou NDIAYE⁴, Saidou Moustapha SALL², Massamba DIOUF⁵, Cheikh Momar NGUER¹ 10

11 ¹ Groupe de Recherche Biotechnologies Appliquées & Bioprocédés Environnementaux, École 12 Supérieure Polytechnique, Université Cheikh Anta Diop de Dakar, Corniche Ouest BP : 5085 Dakar-13 Senegal; fatou54.thiam@ucad.edu.sn (F.T.), malick.diouara@ucad.edu.sn (A.A.M.D.), Fann, anoumbachloe@gmail.com (S.C.C.A.N.), kebe.khadim@esp.sn (K.B.), azoozeng@hotmail.com (A.S.), 14 15 djibabadjoumoi@gmail.com (D.D.), mamendew.mbaye@esp.sn (M.N.M.), sarbandingsane@esp.sn (S.S.), seynaboucoundoul@esp.sn (S.C.), sophiedelitene@esp.sn (S.D.T.), mamadou.diop1@esp.sn 16 17 (M.D.), <u>cmnguer@gmail.com</u> (C.M.N.) 2 Laboratoire Physique de l'Atmosphère et de l'Océan-Siméon Fongang, École Superieure 18 Polytechnique, Université Cheikh Anta Diop de Dakar, Corniche Ouest BP : 5085 Dakar-Fann, Dakar 19 20 10700 Senegal; ibrahima23.diouf@ucad.edu.sn (I.D.), abdoulahat.dieng@ucad.edu.sn (A.L.D.), 21 saidou.sall@ucad.edu.sn (S.M.S) 22 ³ Laboratoire d'Imagerie Médicale et de Bio-Informatique, École Superieure Polytechnique, Université 23 Cheikh Anta Diop de Dakar, Corniche Ouest BP : 5085 Dakar-Fann, Senegal ; idv.diop@esp.sn (I.D.) 24 4 Laboratoire Mathématiques Appliquées et Informatique, Faculté des Sciences et Techniques, 25 Université Cheikh Anta Diop de Dakar, Corniche Ouest BP : 5085 Dakar-Fann, Senegal;

mamadou1.ndiaye@unchk.edu.sn (M.N.) 26

27 ⁵ Laboratoire Sante Publique, Institut d'odontologie et de Stomatologie, Faculte de Medecine, de 28 Pharmacie et d'Odonthologie, Université Cheikh Anta Diop de Dakar, Corniche Ouest BP : 5085 Dakar-Fann, Senegal; massamba.diouf@ucad.edu.sn (M.D.). 29

30

31 * Correspondence: Email address: fatou54.thiam@ucad.edu.sn (F.T.); Tel: +221786300621

01	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2024.01.28.24301904; this version posted January 30, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

Abstract.

Cross-sectional survey was conducted to assess the true extent of COVID-19 exposure among students and staff of Polytechnic High School (PHS). Random cluster sampling was carried out between May 19 and August 18, 2022, after the fourth wave of COVID-19 transmission. IgM and IgG SARS-CoV-2 antibodies were screened using WANTAI SARS-CoV-2 ELISA assays. Seroprevalence and descriptive statistics were calculated. Moreover, the associations between seropositivity and different factors (age, gender, preventive, etc.) were determined using logistic regression. A total of 637 participants were recruited, including 563 students, followed by 52 TAS officers, and 22 professors. The median age among was 21 years [18 - 63]. 62.0% of the participants were female, and 36.89% were male, with a male-to-female ratio = 0.59. The overall IgG and IgM seroprevalence were 92% and 6.91% respectively. We found a higher IgM seroprevalence in men than women (9.4% vs. 5.6%) and a lower IgM seroprevalence in (18-25) age group compared to (55-65) years. Low compliance with preventive measures was found with a significant IgM seroprevalence depending on non-respect of social distancing (p = 0.008). IgM seropositivity was associated with Body Mass Indice (BMI) categorized (O.R. 0.238, p = 0.043), ethnic group (O.R. 0.723, p = 0.046) and marital status (O.R. 2.399, p = 0.021). Moreover, IgG seropositivity was associated with vaccination status (O.R. 4.741, p < 0.001). Our study revealed that the majority of students and staff have already been exposed to SARS-CoV-2, which confirms the circulation of SARS-CoV-2 in PHS at the time of the survey. Our results underline the importance of seroepidemiological surveys to estimate the real impact of the COVID-19 pandemic in a community and to monitor disparities in antibody response in the population. Keywords: COVID-19; SARS-CoV-2 antibodies; sero-epidemiological survey; Polytechnic High School; Senegal.

91 Introduction

- 92 The Coronavirus 2019 (COVID-19), newly identified in December 2019 in Wuhan, China, is an infectious disease caused by Severe Acute Respiratory Syndrome 93 Coronavirus 2 (SARS-CoV-2) [1, 2]. On January 30 2020, the World Health 94 Organization (WHO) declared COVID-19 a public health emergency of global concern, 95 and on March 11, 2020, it announced the COVID-19 epidemic as a pandemic [3]. By 96 November 12, 2023, more than 697 million of people had been infected worldwide, 97 with over 6.9 million deaths [4]. 98 99 The COVID-19 outbreak had substantial economic, social, and health repercussions
- and damaging educational consequences [5-7]. In April 2020, the World Bank 100 estimated that higher education institutions had been closed in 175 countries and that 101 studies had been interrupted or significantly disrupted due to COVID-19, affecting 102 more than 220 million students [8]. The pandemic forced academic communities to 103 adopt online platforms for the continuity of teaching and learning activities, negatively 104 impacting learning outcomes, particularly in developing countries where the lack of 105 network infrastructures, computers, and internet access is challenging distance 106 learning in developing countries [9, 10]. 107
- In Senegal, a West African country, the first case of SARS-CoV-2 was identified on
- March 2, 2020. Since then, the number of cases has risen considerably, and the country
- 110 currently has more than 89,022 confirmed cases of COVID-19 and 1,971 deaths [11].
- 111 The onset of the pandemic led the government authorities to close higher education
- establishments from March 16 to August 31 2020. The reopening of the establishments
- 113 took place with the introduction of sanitary protocols that emphasized the
- reinforcement of barrier measures (wearing masks, hand washing with soapy water
- 115 or hydroalcoholic gel, respect for social distancing and systematic taking of body
- temperature at campus access points) [12]. However, these measures have often been insufficient to stem the spread of the virus. Clusters quickly appeared in some
- insufficient to stem the spread of the virus. Clusters quickly appeared in someestablishments, including the Cheikh Anta Diop (CAD) University, located in Dakar,
- 119 the capital of Senegal.
- 120 The failure of strategies to combat the spread of the virus could be linked to multiple
- 121 factors, including (i) CAD University ecosystem, with its over 80,000 students from
- 122 diverse origins. The consequence is overcrowding in student residences that caused
- 123 the spread of the virus; (ii) the university environment is mainly populated by young
- 124 people, who do not seem to be fully aware of the risks associated with the COVID-19
- health crisis [13]; (iii) the promiscuity in the Halls of residence, making it difficult to
- 126 comply with social preventive measures; (iv) Lastly, lack of vaccine deployment and
- reluctance was noted among young people, which also contributes to low vaccination
- 128 coverage in universities [14].
- 129 Faced with all these difficulties, it was essential to adopt cyclical measures to manage
- the COVID-19 pandemic, characterised by the virus spreading in waves [15, 16]. These
- 131 measures could involve introducing survey studies based on diagnostic testing and
- mass screening protocols to diagnose and follow up with people exposed to or infected
- with SARS-CoV-2. In practice, detecting viral RNA by RT-PCR is the reference method
 for confirming the diagnosis of SARS-CoV-2 infection [17, 18]. However, access to

diagnostic tests still needs to be improved in poor countries [19]. The other way to 135 estimate the true extent of the epidemic is to conduct Seroprevalence surveys [20, 21]. 136 Seroepidemiological studies to detect the presence of anti-SARS-CoV-2 antibodies are 137 a valuable tool for assessing the timing of the epidemic. It can help to confirm the 138 presence of a recent infection when PCR is limited. Some antibodies, such as IgG, can 139 even be detected years after exposure [22]. Their detection can be used to identify 140 previous or recent exposure to SARS-CoV-2. By carrying out this analysis on a 141 representative population, it is possible to estimate what proportion of the population 142 has already been exposed to the new coronavirus [23]. This information is helpful in 143 identifying the epidemic phases and can help the authorities make decisions and even 144 anticipate appropriate measures to contain the pandemic's spread [24]. Sero-145 epidemiological studies have been conducted in academic institutions such as 146 universities in many countries [25-28]. However, more studies are highly relevant 147 because university communities (faculty, staff and students) could be among the most 148149 exposed to SARS-CoV-2. In Senegal, no seroprevalence studies have been conducted in cohorts of educational institutions. 150

Therefore, we conducted an on-site screening project at Polytechnic High School (PHS), 151

152 a public institution with an inter-African vocation at CAD University from May to August 2022 after the fourth wave of Coronavirus disease in Senegal. We aimed to 153

assess the true extent of previous and recent COVID-19 exposition among students 154 and staff and to investigate the risk factors associated with SARS-CoV-2 IgM and IgG 155 seropositivity. 156

157

2. Materials and Methods 158

159

2.1. Study Design and Population 160

The SARSESP ("Etude de Seroprevalence du SARS-CoV-2 au sein de l'École Su-161 périeure Polytechnique", in the Cheikh anta DIOP University (CAD University)) 162 project is an on-site university population-based cross-sectional study. The sampling 163 occurred at the PHS, an establishment of CAD University. Students, Professors, and 164 Technicians, Administrative and Service (TAS) officers at SPS were invited by e-mail 165 to enrol in the study. Participants were volunteers who registered online between 19 166 May and 18 August 2022. A questionnaire was administered to each participant after 167 consent, blood samples were taken for SARS-CoV-2 antibody detection. 168

169

2.2. Sample Size Calculation 170

We used stratified random sampling: the first stratum concerned professors, the 171 second TAS officers and the third students. Systematic random sampling was used 172 within each stratum to determine the required number of subjects. Using the lists 173 174 provided by the student affairs and human resources departments, we calculated the sample size based on the hypothesis of an expected seroprevalence of 45%, with a 175 precision of 5%, a design effect of 1.96, and a nonresponse rate of 65%. We determined 176 177 that >450 participants needed to be recruited. To increase the accuracy of the results, this size was multiplied by 2, giving a sample size of 898, and rounded up to 1000 to 178

account for any lost records. The survey step for selecting statistical units was 179 6133/1000, i.e. a step = 6. In this study, an allocation proportional to the size of each 180 stratum was used. Thus, we considered a proportion of 83.54% for students, 9.97% for 181 professors and 6.47% for TAS officers. Then, we obtained 65 TAS officers, 100 182 professors and 835 students. The inclusion criteria were age over eighteen (18) years, 183 informed consent signed, and questionnaire completion. Then, the non-inclusion 184criteria were under 18 years of age, non-consent and contraindications to venous blood 185 sampling (anaemia, Infection or hematoma at a prospective venipuncture site, etc.). 186

- 187
- 2.3. *Questionnaire* 188

We shared an interviewer-administered questionnaire with participants on an 189 electronic tablet (https://enquete.ucad.sn/index.php/598685?lang=fr). The 190 questionnaire covered points regarding different factors to assess for relationships 191 between IgM and IgG seropositivity and these factors. Questions relating to 192 193 sociodemographic characteristics were collected, such as age, sex, occupation, education level, nationality, ethnic group and accommodation type. We also collected 194 alcohol and tobacco intake, SARS-CoV-2 vaccination status, and preventive measures 195 196 related to SARS-CoV-2 practices. We provided all recruitment participants with face masks and hand sanitisers and encouraged them to practice physical and social 197 distancing. The questionnaire on COVID-19 was posted online by the IT and 198 199 Information Systems Department of CAD University.

200

2.4. Blood Collection and SARS-CoV-2 Antibodies Detection 201

After each participant signed the written consent form, a 10 mL whole blood sample 202 was collected into a dry vacutainer tube by standard venipuncture technique. Blood 203 samples were centrifuged at 2,500 rpm for 10 minutes. Then, the plasma was collected 204 and stored in cryotubes at -80°C at the GRBA-BE laboratory biobank in PHS until the 205 tests were carried out. Seropositivity to anti-SARS-CoV-2 antibodies was used as a 206 biomarker of exposure to the SARS-CoV-2 virus. IgM class immunoglobulins were 207 used as a marker of recent or current infection (usually from days 5-7 after symptoms 208 appear, but sometimes later and decrease at days 15-22), and IgG class 209 immunoglobulins were used as a biomarker of older infection (detectable from day 11 210 post symptom, reaching a maximum 3-4 weeks after and persist days 90 after) [29, 30]. 211 Serological tests were performed by qualitative ELISA for IgM and quantitative ELISA 212 for IgG following the instructions for the WANTAI SARS-CoV-2 IgM ELISA (Beijing 213 Wantai Biological Pharmacy Enterprise, Beijing, China; Ref. WS-1196 and WS-1396) 214 recommended by the WHO for seroepidemiological studies, which detects total 215 antibodies (including IgM and IgG) binding the SARS-CoV-2 spike protein receptor 216 binding domain (S1/RBD) [31]. Serum samples were analysed in duplicate according 217 218 to the supplier's recommendations.

219

220 2.5. Statistical Analyses

Statistical analyses were performed using Rstudio (version R 4.2.1) and GraphPad 221

Prism (version 10.1.1 (316)) softwares. Continuous variables were described as mean 222

223 (standard deviation) or median (interguartile range). Normally distributed variables

were compared with a t-test, and nonparametric data were compared with the Mann-

225 Whitney test. Categorical variables were presented as percent, and Fisher exact tests

or chi-squared tests were used for proportional assessments. For all statistical tests, we

227 accepted a two-sided level of significance was set at $p \le 0.05$.

SARS-CoV-2 seroprevalence was defined as the ratio of the number of people who developed anti-SARS-CoV-2 antibodies to the general population. Confidence intervals (95% CI) for seroprevalence were estimated using the Clopper-Pearson method. Using logistic regressions, we sought to understand how the IgM and IgG seropositivity are influenced by various variables such as age, gender, occupation, education level, nationality, type of accommodation, etc. The analyses were carried out after carefully handling the database and processing missing data.

235

236 2.6. *Ethics Statement*

This research complies with ethical recommendations. The project protocol has been validated by the National Health Research Ethics Committee (CNERS) of the Ministry of Health and Social Action. The research protocol was drawn up in accordance with Senegalese laws and regulations governing the confidentiality of personal data. The study was approved by the Senegalese National Ethics Committee for Research in Health (Reference number N°000043/MSAS/CNERS/SP, 28 February 2022).

243

244 **3. Results**

245 3.1. Baseline characteristics of participants

From the 1000 students, professors and TAS officers of PHS who were invited to 246 participate in the study between 19 May 2022 and 18 August 2022, 637 (63.7%) 247 participants were finally included (Figure 1). The most represented group was 248 249 students (88.38%), followed by TAS officers (8.16%), and professors (3.45%). The mean age was 23.20 years, ranging from 18 to 63 years. The population's median age was 21 250 years, with most participants aged 18 to 25 years, representing 85.7% of the population 251 (Table I). 62.0% of the participants were female, and 36.89% were male, with a male-252 to-female ratio = 0.59. Most participants were Senegalese (94.66%) and lived in family 253 homes (54.6%). In addition, most ethnic groups in the PHS population were Wolof 254 (31.24%), Fula (24.33%) and Serer (21.98%). The prevalences of active smoking and 255 taking alcohol were relatively low in the PHS community at the moment of the survey 256 (1.9%) and (3.62%), respectively. Demographic data are shown in Table I. Calculation 257 of body mass index also revealed the highest prevalence of normal weight (37.68%), 258 followed by underweight (10.8%) and overweight/obesity, 8.32%). The most common 259 blood group is O+ (47.08%). At the time of data collection, unvaccinated vs. vaccinated 260 participants were 57.46% and 35.01%) respectively. 261

262

263 3.2. Compliance with preventive measures and antibodies' seroprevalence

Most respondents reported a low level of compliance with the following preventive measures recommended by the health authorities: 31.39% among participants declared that they had worn a mask always or often, and 18.21% observed a physical distance

(minimum 2 m) over the last 15 days. However, most participants reported a high level 267 of compliance with hand washing: 75.35% had washed their hands always or often 268 (Figure 2A). For social distancing, the majority of participants, 71.58%, reported 0-2 269 frequencies of Participation in social events during the 15 days before the survey; 70.8% 270 declared that they used public transport at least 2 times a day; and finally, 62.16% had 271 visited someone 15 days before the survey (Figure 2B). 272

273

307

3.3. Seroprevalence of IgM et IgG SARS-CoV-2 antibodies 274

275 For overall participants, 6.91% (95% CI: 4.93 – 8.87) were seropositive for SARS-CoV-2 IgM antibody, and 92% (95% CI: 89.90 – 94.11) were seropositive for SARS-CoV-2 IgG. 276 Then, we analysed IgM and IgG seroprevalence according to the different 277 278 characteristics of the study population shown in Table II.

279 Regarding IgM seroprevalence, the results showed significant age-dependence (p < p0.001) with higher seroprevalence in the (25-35) age group with 23.69% (95% CI: 20.39) 280 281 - 27) compared to (18-25) age group with 5.5% (95% CI: 3.73 - 7.27). According to gender, IgM seroprevalence was higher in men, 9.4% (95% CI: 7.13 – 11.67) than in 282 women, 5.6% (95% CI: 3.51 - 7.38), but no significant differences were found by sex (p 283 284 = 0.83). There were no significant differences according to the other sociodemographic parameters regarding IgM antibodies seropositivity, such as occupation, level of 285 education, ethnic group, accommodation type and size, but with some differences 286 between sub-groups. For example, depending on the type of residence, we found a 287 higher IgM seroprevalence among those living in halls of residence, 7.97% (95% CI: 288 5.87 – 10.07) compared to those living in family homes, 6.68% (95% CI: 4.74 – 8.62)], p 289 290 = 0.73.

Concerning IgG seroprevalence, we found a significant difference between people 291 who drank alcohol [95.24% (95% CI: 93.58 – 96.89)] and those who didn't [90.80%, (95% 292 CI: 88.55, 93.04)], with p = 0.038. Then, a very significant difference was found 293 according to vaccination status, with a high seropositivity rate in vaccinated people 294 [96.83% (95% CI: 95.47 - 98.19)] compared to unvaccinated [86.58% (95% CI: 83.93 -295 [89.22], p < 0.0001. No significant difference was found between IgG seroprevalence 296 according to age groups, while IgG seroprevalence was lower in men [89.9% (95% CI: 297 87.60 - 92.24)] than in women [90.6% (95% CI: 88.33 - 92.87)], p = 0.98. Then, no 298 significant differences were found by sex (p = 0.83). IgM and IgG seroprevalences were 299 higher in Professors and TAS officers than in students, yet this difference was not 300 statistically significant (p = 0.71). 301

Concerning antibodies' seroprevalence according preventive measures, we found a 302 significant difference in IgM seroprevalence according to the 'number of visits made 303 to someone' during the 15 days before the survey (p = 0.008) (Table III). However, we 304 found no significant difference in IgG seroprevalence and compliance with barrier 305 306 measures.

308 3.5. Risk factors associated with SARS-CoV-2 IgM and IgG seropositivity among PHS 309 community

Multiple Logistic regression analysis didn't show an association between IgG 310 seropositivity and the factors studied. Interestingly, an association between IgM 311 seropositivity and participants' ethnic group [O.R. 0.72395% CI: 0.49 - 0.96, (p = 0.046)]312 was reported (Table IV). Using a univariate analysis, we found a significant association 313 between IgM seropositivity and marital status [O.R. 2.399 95% CI: 1.08 - 4.87 (p = 314 0.021)], and Body Mass Indice (BMI) categorised [O.R. 2.015 95% CI: 1.12 – 3.56, (p = 315 0.016)]. In addition, on one hand, we found a significant association between 316 vaccination and IgG seropositivity [O.R. 4.741 95% CI: 2.25 – 11.65, (*p* < 0.001)]; on the 317 other hand, no associations were observed between SARS-CoV-2 seropositivity and 318 sex and age groups. Finally, no significant association were found between IgM and 319 IgG seropositivity and preventive measures (Table V). 320

321 322

323 4. Discussion

324 This is the first sero-epidemiological survey of COVID-19 carried out in an educational establishment in Senegal. The study aimed to determine the seroprevalence of IgM 325 and IgG SARS-CoV-2 antibodies and associated risk factors in order to assess the 326 327 extent of virus exposure within the Polytechnic High School in Cheikh Anta Diop University. The survey was carried out on samples collected from personnel and 328 students from May 2022 to August 2022, after the fourth wave of COVID-19 in Senegal. 329 A total of 637 participants were included in the study, 62% of whom were women and 330 37% men. The median age was 21, which is justified by the fact that the study was 331 conducted in a university environment. Consequently, the study population 332 predominantly comprises students representing around 86% of the participants. 333

We showed high IgG and IgM SARS-CoV-2 antibody seroprevalences of 92% (95% CI: 334 89.90 – 94.11) and 6.91% (95% CI: 4.93 – 8.87), respectively. The IgM seroprevalence 335 336 indicates that the virus was circulating within PHS at the time of the survey, with people who were currently or recently infected. Indeed, in seroprevalence surveys, it 337 is recommended to use IgM and IgG detection to diagnose recent and previous 338 infections [32]. IgM antibody levels rise around a week after the initial infection, 339 indicating a recent infection [22]. IgG antibodies appear later than IgM antibodies 340 (generally within 14 days of infection). They can persist for up to a year [33, 34], 341 meaning that IgG antibodies serve as an indicator of an old infection [35]. 342

The very IgG high seroprevalence could be due to increased exposure to the SARS-343 CoV-2 virus and the anti-COVID vaccination policy implemented by the authorities. 344 Data from the Ministry of Health showed that our study occurred after the fourth wave 345 of COVID-19 in Senegal in January 2022, and the deployment of the COVID-19 vaccine 346 began in February 2021 [36], which could explain our result. The first seroprevalence 347 surveys carried out in Senegal were conducted in 2020 after the first wave and showed 348 349 a lower seroprevalence of around 20%. Between June and September 2020, Seck et al. found a SARS-CoV-2 seroprevalence rate of 21.1% (95% CI = 16.7–26.1%) [37]. During 350 351 the same period, Ahouidi et al. conducted a study between June and October 2020. 352 They found that the overall positivity rate was 20.4% and significant geographical differences in seropositivity with a higher seroprevalence in Dakar, around 40% [38]. 353

Then, Talla et al. found an adjusted national prevalence of anti-SARS-CoV-2 IgG/IgM 354 in Senegal estimated to be 28.4% between October 24 and November 26, 2020 [39]. A 355 high SARS-CoV-2 seroprevalences and its variability between localities were also 356 reported in the second national population based cross-sectional survey (72,2%) 357 conducted in November 2021 [40] and among pregnant women attending the 358 antenatal consultation (69,4%) during the second and third waves of COVID-19 in 359 Senegal [41]. 360

Results showed a sharp increase in seroprevalence since 2020 in Senegal, and data 361 corroborating the finding that several variants have circulated in the country, 362 including the delta variant, which has been the most deadly and caused a peak in the 363 number of confirmed cases in July 2021 [42]. Study carried out in Africa at the same 364 time as our survey showed similarly high seroprevalence, with 74% between July and 365 August 2022 in Bangui, Central African Republic [43]. In Nigeria, in early 2021, there 366 was a high SARS-CoV-2 seroprevalence of 72.4% [44]. Given this situation, it seems 367 very important to carry out cyclical epidemiological survey studies to measure the 368 extent of the spread of the SARS-CoV-2. 369

Interestingly, we found a higher IgM seroprevalence in men than women (9.4% vs. 370 371 5.6%). Then, our result would suggest that men are more sensitive to infection and/or reinfection with SARS-CoV-2 than women. A study conducted at the start of the 372 pandemic by Takahashi et al. showed that men were more susceptible to severe forms 373 374 of COVID-19 than women [45]. Gender differences in immune responses were also reported, with higher levels of pro-inflammatory cytokines (IL-8 and IL-18) and a 375 more robust induction of non-classical monocytes in men [46]. This is consistent with 376 studies that analysed the sex difference in antibody responses [47]. In further studies, 377 it will be interesting compare immune responses according to gender and serological 378 status in order to discover the mechanisms underlying sex differences. 379

380 Our results also showed a different distribution by age group, with lower IgM seroprevalence in younger individuals, particularly those aged 18-25 years, compared 381 to those aged 55-65 years (5.5% and 33.34%, respectively) with a *p* < 0,001. The 18-25 382 age group appears less affected by recent infections. This reinforces the data showing 383 that young people are less affected by SARS-CoV-2 infection [48]. Furthermore, they 384 often experience an asymptomatic or mild SARS-CoV-2 infection associated with 385 lower serum titers [49]. In Senegal, during the first wave, it was reported that 386 seroprevalence of SARS-CoV-2 was higher in patients older than 65 years [37]. 387

We investigated whether there was a link between the type of residence and IgM 388 seroprevalence to determine the proportion of new infections accordingly. 389 Surprisingly, we didn't find a significant difference in terms of IgM seroprevalence 390 among those living in halls of residence [7.97% (95% CI: 5.87 - 10.07)] compared to 391 those living in family homes [6.68% (95% CI: 4.74 - 8.62)], p = 0.73. This invalidates our 392 393 hypothesis that the particular ecosystem of CAD University, with its over 80,000 students from diverse origins, would constitute a niche for spreading the virus, which 394 395 is not proven in our study. It also appears that, even though the PHS community is 396 mainly be composed by young people, they do not seem to facilitate new infection, contrary to what has been reported in other studies [48, 50]. 397

Concerning compliance with preventive measures, we found a low level of compliance 398 with preventive measures recommended by the health authorities, particularly for 399 wearing masks (31.40%) and keeping a physical distance (minimum 2 m) (17.42%). 400 However, most participants reported high-level compliance with hand washing 401 (75.35%). Social distancing and staying at home were also registered although to a 402 lower degree. Our results were in contradiction with those of Kearney et al. who 403 observed high compliance with recommended COVID-19 prevention behaviors 404 among their sample of Senegal respondents, particularly for masking and personal 405 hygiene practices [51]. This difference could be explained by the fact that our study 406 population is younger and less inclined to comply with preventive measures [52, 53]. 407

Our findings revealed that IgM seropositivity depends on the 'number of visits made 408 to someone', meaning non-respect of social distancing (p = 0.008), which shows the 409 importance of WHO measures concerning the adoption of extensive social distancing 410 as a non-pharmaceutical intervention to reduce the infection's spread and the 411 412 associated mortalities [54]. However, studies have shown that the impact of social distancing measures depends upon a host of demographic, environmental, and 413 economic dimensions [55]. 414

Regarding vaccination, around 35% of participants had been partially or totally 415 vaccinated, which is higher than the national vaccination rate of 16.9% at the moment 416 of the survey [56]. This could be explained by our population's education level and 417 knowledge of vaccination's stakes. Efforts were also made by the CAD University 418authorities, who set up a vaccination campaign at various sites during October 2021. 419 However, the vaccination rate remains low compared to the national level, where more 420 than 70% of the population vaccinated since the pandemic started [57]. 421

Furthermore, we found no significant differences in IgM seroprevalences between 422 vaccinated and unvaccinated individuals. It would, therefore, appear that vaccination 423 424 does not protect against the new variants and reinfections, as has already been demonstrated in numerous studies [58-60] indeed, WHO recommendations suggest 425 that seasonal vaccination is necessary to protect against new variants [61]. 426

We investigated the association of sociodemographic, clinical and lifestyle factors, 427 such as BMI, blood type, smoking and alcohol consumption, with seropositivity using 428 logistics. Then, we found an association between BMI categorised and IgM 429 seropositivity (O.R. 0.238, p = 0.043). Previous studies have shown that obese 430 individuals (BMI > 30 kg/m^2) were significantly more likely to be seropositive. It is 431 uncertain whether the raised seroprevalence in these groups represents a greater risk 432 of SARS-CoV-2 infection. However, obese individuals are known to experience more 433

severe COVID-19 symptoms [62, 63]. 434

- Interestingly, a significant association between IgM seropositivity and ethnic group 435
- was found (O.R. 0.723, p = 0.046), suggesting a difference in susceptibility to SARS-436
- 437 CoV2- depending on race and ethnicity. According to previous findings, it seems there
- are disparities in the effects of COVID-19 infection among different racial/ethnic 438
- groups [64, 65]. Then, understanding the mechanisms for the disparity will help to 439
- evaluate the risk for COVID-19 according to ethnicity. 440

medRxiv preprint doi: https://doi.org/10.1101/2024.01.28.24301904; this version posted January 30, 2024. The copyright holder for this preprint doi: https://doi.org/10.1101/2024.01.20.24.01.904, funder for this version posted sandary 30, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Our findings showed that IgM seropositivity was associated with marital status 441 (unmarried/married) (O.R. 2.39, *p* = 0.021); another study reveals that transmission of 442 SARS-CoV-2 is variable among different people within the home. For instance, the risk 443 for infection was higher between spouses, at 43%, which could be a reflection of 444 transmission through intimacy or longer or more direct exposure [66]. 445

Regarding vaccination status, we found a relationship between vaccination and IgG 446

seroprevalence (O.R. 4.741, p < 0.001), showing that people who had received vaccine 447

doses were four times more likely to produce anti-SARS-CoV-2 antibodies than those 448

who had not. It will be interesting to determine the IgG-neutralizing antibodies and to 449 determine antibody levels according to vaccination status and type. Indeed, it has been 450

shown that vaccines from different manufacturers might induce different antibody 451

- responses [67]. 452
- 453

Some limitations of our study must be considered. By design, we carried out an on-454 site university population-based cross-sectional study. Thus, the results cannot be 455 extrapolated directly to the general CAD University population. Participants were 456 subjected to recall bias when completing the questionnaires, particularly preventive 457 measures at the time of contact. We also noted a very low level of participation from 458professors and TAS officers. This constitutes a bias in the statistical calculations. 459 Missing data for certain criteria and non-prefer responders were a limitation for 460 statistics. To date, our study is the only SARS-CoV-2 sero-epidemiological survey 461 conducted in a university community in Senegal. Data on the Serological testing 462 performed by measuring IgM and IgG immunoglobulins against the SARS-CoV-2 463 targeting peak S1 protein separately is a strength of our study. This allowed us to 464 differentiate recent from previous infection. Finally, with our questionnaire we were 465 able to collect a lot of data, which was useful in calculating associations with risk 466 factors. 467

468

In summary, our analysis of more than 630 subjects from Polytechnic High School 469 community members estimated the extent of exposure to SARS-CoV-2. Our study 470 revealed a high seroprevalence from May-August 2022 following the fourth wave of 471 COVID-19 in Senegal. Our results show that the majority of students and staff have 472 already been exposed to SARS-CoV-2 and confirm the circulation of the virus (SARS-473 CoV-2) at the time of the survey as shown by the high IgM and IgG seroprevalence. 474 The data show a link between seropositivity and various factors such as age, non-475 compliance with prevention measures. These results underline the importance of sero-476 epidemiological surveys to estimate the real impact of the COVID-19 pandemic and 477 the disparities between populations in order to establish a profile of the transmission 478 dynamics of the virus. In addition, these results may be essential for the CAD 479 480 university in the event of the emergence of future waves in order to make appropriate decisions and put in place means of monitoring the evolution of the pandemic after 481 the relaxation of social distancing measures and the implementation of a vaccination 482 483 schedule at CAD University, which will serve as a basis for other universities in Senegal. 484

Author Contributions: "Conceptualization, F.T. and A.A.M.D, C.M.N, M.D.; 485 methodology, F.T., A.A.M.D., C.S.C.A.N., S.S., S.D.T, S.C., A.S., D.D., and M.N.M; 486 software, F.T., C.S.C.A.N., I.D., D.D., K.K., I.D.; A.L.D, M.D..; validation, F.T., 487 A.A.M.D., C.M.N., S.M.S.; formal analysis, F.T., K.K, C.S.C.A.N., I.D., D.D.; A.L.D., 488 M.D.; investigation, sample collection and biobank management, F.T., A.A.M.D., 489 M.N.M, C.S.C.A.N, D.D., S.C., S.S., S.D.T., A.S.; resources, F.T., A.A.M.D., S.M.S, M.D.; 490 data curation, F.T., S.S., C.S.C.A.N., D.D.; writing-original draft prepa-ration, F.T.; 491 writing-review and editing, F.T., A.A.M.D., MNM, MD, CMN, KK, ID, SMS; 492 visualization, F.T, A.A.M.D.; supervision, F.T., A.A.M.D., S.M.S., M.D., C.M.N; project 493 administration, F.T.; funding acquisition, F.T., A.A.M.D., and C.M.N. All authors have 494 read and agreed to the published version of the manuscript 495

496

499

497 Funding: This research was funded by Polytechnique High School competitive498 research impulse fund.

Institutional Review Board Statement: The study was conducted in accordance with
the Decla-ration of Helsinki, and approved approved by the Senegalese National
Ethics Committee for Research in Health (Reference number
N°000043/MSAS/CNERS/SP, 28 February 2022).

504

505 **Informed Consent Statement:** Informed consent was obtained from all subjects 506 involved in the study.

507

508 **Data Availability Statement:** Not applicable.

509

510 **Acknowledgments:** The authors would like to thank the top management of the 511 "Ecole Supéri-eure Polytechnique de Dakar" for financial support and all students, 512 Technicians, Administrative, Service officer and professors' members who voluntarily 513 participated to the study.

514

515 **Conflicts of Interest:** The authors declare no conflict of interest. The funders had no 516 role in the design of the study; in the collection, analyses, or interpretation of data; in 517 the writing of the manuscript; or in the decision to publish the results".

518

519 **References**

 Asselah T, Durantel D, Pasmant E, Lau G, Schinazi RF. COVID-19: Discovery, diagnostics and drug development. J Hepatol. 2021;74(1):168-84. Epub 20201008. doi: 10.1016/j.jhep.2020.09.031.
 PubMed PMID: 33038433; PubMed Central PMCID: PMCPMC7543767.

Yesudhas D, Srivastava A, Gromiha MM. COVID-19 outbreak: history, mechanism,
 transmission, structural studies and therapeutics. Infection. 2021;49(2):199-213. Epub 20200904. doi:
 10.1007/s15010-020-01516-2. PubMed PMID: 32886331; PubMed Central PMCID: PMCPMC7472674.

526 3. WHO Director-General's opening remarks at the media briefing on COVID19 -March 2020.

527 4. https://www.worldometers.info/coronavirus/ (accessed November 12, 2023).

528 5. Mofijur M, Fattah IMR, Alam MA, Islam A, Ong HC, Rahman SMA, et al. Impact of COVID-19 529 on the social, economic, environmental and energy domains: Lessons learnt from a global pandemic.

530 Sustain Prod Consum. 2021;26:343-59. Epub 20201014. doi: 10.1016/j.spc.2020.10.016. PubMed PMID: 531 33072833; PubMed Central PMCID: PMCPMC7556229.

532 Hosseinzadeh P, Zareipour M, Baljani E, Moradali MR. Social Consequences of the COVID-19 6. 533 Pandemic. A Systematic Review. Invest Educ Enferm. 2022;40(1). doi: 10.17533/udea.iee.v40n1e10. 534 PubMed PMID: 35485623; PubMed Central PMCID: PMCPMC9052715.

535 7. Shang Y, Li H, Zhang R. Effects of Pandemic Outbreak on Economies: Evidence From Business History Context. Front Public Health. 2021;9:632043. Epub 20210312. doi: 10.3389/fpubh.2021.632043. 536 537 PubMed PMID: 33777885; PubMed Central PMCID: PMCPMC7994505.

538 8. World Bank Open Data. Data. https://data.worldbank.org/ (2021).

9. Mok KH. Impact of COVID-19 on Higher Education: Critical Reflections. High Educ Policy. 539 2022;35(3):563-7. Epub 20220811. doi: 10.1057/s41307-022-00285-x. PubMed PMID: 35971428; PubMed 540 541 Central PMCID: PMCPMC9365678.

542 Selvaraj A, Radhin V, Ka N, Benson N, Mathew AJ. Effect of pandemic based online education 10. 543 on teaching and learning system. Int J Educ Dev. 2021;85:102444. Epub 20210608. doi: 544 10.1016/j.ijedudev.2021.102444. PubMed PMID: 34518732; PubMed Central PMCID: PMCPMC8426326.

https://www.worldometers.info/coronavirus/country/senegal/ 545 11. (accessed 546 November 12, 2023).

547 Diallo AI, Faye A, Tine JAD, Ba MF, Gaye I, Bonnet E, et al. Factors associated with the 12. 548 acceptability of government measures to address COVID-19 in Senegal. Rev Epidemiol Sante Publique. 549 2022;70(3):109-16. Epub 20220331. doi: 10.1016/j.respe.2022.03.123. PubMed PMID: 35491335; PubMed 550 Central PMCID: PMCPMC8968153.

551 Ba MF, Ridde V, Diallo AI, Tine JAD, Kane B, Gaye I, et al. Acceptability of contact management 13. 552 and care of simple cases of COVID-19 at home: a cross-sectional study in Senegal. Trans R Soc Trop Med 553 Hyg. 2022;116(12):1214-22. doi: 10.1093/trstmh/trac094. PubMed PMID: 36222221; PubMed Central 554 PMCID: PMCPMC9619604.

555 14. Nguyen KH, Nguyen K, Mansfield K, Allen JD, Corlin L. Child and adolescent COVID-19 vaccination status and reasons for non-vaccination by parental vaccination status. Public Health. 556 2022;209:82-9. Epub 20220613. doi: 10.1016/j.puhe.2022.06.002. PubMed PMID: 35870290; PubMed 557 558 Central PMCID: PMCPMC9189141.

559 Zhou Y, Rahman MM, Khanam R. The impact of the government response on pandemic control 15. 560 in the long run-A dynamic empirical analysis based on COVID-19. PLoS One. 2022;17(5):e0267232. Epub 20220504. doi: 10.1371/journal.pone.0267232. PubMed PMID: 35507588; PubMed Central PMCID: 561 PMCPMC9067654. 562

563 Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G, et al. Living with the 16. COVID-19 pandemic: act now with the tools we have. Lancet. 2020;396(10259):1314-6. Epub 20201008. 564 565 doi: 10.1016/S0140-6736(20)32117-6. PubMed PMID: 33038947; PubMed Central PMCID: 566 PMCPMC7544497.

17. Torretta S, Zuccotti G, Cristofaro V, Ettori J, Solimeno L, Battilocchi L, et al. Diagnosis of SARS-567 CoV-2 by RT-PCR Using Different Sample Sources: Review of the Literature. Ear Nose Throat J. 568 2021;100(2_suppl):131S-8S. Epub 20200831. doi: 10.1177/0145561320953231. PubMed PMID: 32865458; 569 570 PubMed Central PMCID: PMCPMC7459180.

571 18. Chung YS, Lee NJ, Woo SH, Kim JM, Kim HM, Jo HJ, et al. Validation of real-time RT-PCR for 572 detection of SARS-CoV-2 in the early stages of the COVID-19 outbreak in the Republic of Korea. Sci Rep. 2021;11(1):14817. Epub 20210720. doi: 10.1038/s41598-021-94196-3. PubMed PMID: 34285290; 573 PubMed Central PMCID: PMCPMC8292370. 574

575 Maniruzzaman M, Islam MM, Ali MH, Mukerjee N, Maitra S, Kamal MA, et al. COVID-19 19. 576 diagnostic methods in developing countries. Environ Sci Pollut Res Int. 2022;29(34):51384-97. Epub 20220527. doi: 10.1007/s11356-022-21041-z. PubMed PMID: 35619009; PubMed Central PMCID: 577 PMCPMC9135468. 578

579 20. Lai CC, Wang JH, Hsueh PR. Population-based seroprevalence surveys of anti-SARS-CoV-2 580 antibody: An up-to-date review. Int J Infect Dis. 2020;101:314-22. Epub 20201009. doi: 581 10.1016/j.ijid.2020.10.011. PubMed PMID: 33045429; PubMed Central PMCID: PMCPMC7546669.

Rostami A, Sepidarkish M, Leeflang MMG, Riahi SM, Nourollahpour Shiadeh M, Esfandyari S, 582 21. 583 et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clin Microbiol 584 Infect. 2021;27(3):331-40. Epub 20201024. doi: 10.1016/j.cmi.2020.10.020. PubMed PMID: 33228974; 585 PubMed Central PMCID: PMCPMC7584920.

586 22. Hou H, Wang T, Zhang B, Luo Y, Mao L, Wang F, et al. Detection of IgM and IgG antibodies in 587 patients with coronavirus disease 2019. Clin Transl Immunology. 2020;9(5):e01136. Epub 20200506. doi: 10.1002/cti2.1136. PubMed PMID: 32382418; PubMed Central PMCID: PMCPMC7202656. 588

589 23. Feikin DR, Widdowson MA, Mulholland K. Estimating the Percentage of a Population Infected 590 with SARS-CoV-2 Using the Number of Reported Deaths: A Policy Planning Tool. Pathogens. 2020;9(10). 591 Epub 20201013. doi: 10.3390/pathogens9100838. PubMed PMID: 33066231; PubMed Central PMCID: 592 PMCPMC7602107.

593 24. Cascini F, Failla G, Gobbi C, Pallini E, Hui J, Luxi W, et al. A cross-country comparison of Covid-594 19 containment measures and their effects on the epidemic curves. BMC Public Health. 2022;22(1):1765. 595 Epub 20220917. doi: 10.1186/s12889-022-14088-7. PubMed PMID: 36115936; PubMed Central PMCID: 596 PMCPMC9482299.

597 25. Vusirikala A, Whitaker H, Jones S, Tessier E, Borrow R, Linley E, et al. Seroprevalence of SARS-598 CoV-2 antibodies in university students: Cross-sectional study, December 2020, England. J Infect. 599 2021;83(1):104-11. Epub 20210429. doi: 10.1016/j.jinf.2021.04.028. PubMed PMID: 33933527; PubMed 600 Central PMCID: PMCPMC8081745.

601 26. Tsitsilonis OE, Paraskevis D, Lianidou E, Pierros V, Akalestos A, Kastritis E, et al. 602 Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report. Life (Basel). 2020;10(9). Epub 603 604 20200921. doi: 10.3390/life10090214. PubMed PMID: 32967110; PubMed Central PMCID: 605 PMCPMC7555935.

606 27. Arnold CRK, Srinivasan S, Rodriguez S, Rydzak N, Herzog CM, Gontu A, et al. SARS-CoV-2 607 Seroprevalence in a University Community: A Longitudinal Study of the Impact of Student Return to Campus on Infection Risk Among Community Members. medRxiv. 2021. Epub 20210917. doi: 608 609 10.1101/2021.02.17.21251942. PubMed PMID: 33619497; PubMed Central PMCID: PMCPMC7899462.

610 28. Migliara G, Renzi E, Baccolini V, Cerri A, Donia P, Massimi A, et al. Predictors of SARS-CoV-2 611 Infection in University Students: A Case-Control Study. Int J Environ Res Public Health. 2022;19(21). Epub 20221103. doi: 10.3390/ijerph192114376. PubMed PMID: 36361257; PubMed Central PMCID: 612

PMCPMC9655450. 613

614 29. Denning DW, Kilcoyne A, Ucer C. Non-infectious status indicated by detectable IgG antibody 615 to SARS-CoV-2. Br Dent J. 2020;229(8):521-4. Epub 20201023. doi: 10.1038/s41415-020-2228-9. PubMed PMID: 33097885; PubMed Central PMCID: PMCPMC7582419. 616

Assaid N, Arich S, Charoute H, Akarid K, Anouar Sadat M, Maaroufi A, et al. Kinetics of SARS-617 30. 618 CoV-2 IgM and IgG Antibodies 3 Months after COVID-19 Onset in Moroccan Patients. Am J Trop Med Hyg. 2023;108(1):145-54. Epub 20221212. doi: 10.4269/ajtmh.22-0448. PubMed PMID: 36509045; PubMed 619

620 Central PMCID: PMCPMC9833093.

GeurtsvanKessel CH, Okba NMA, Igloi Z, Bogers S, Embregts CWE, Laksono BM, et al. An 621 31. 622 evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nat 623 Commun. 2020;11(1):3436. Epub 20200706. doi: 10.1038/s41467-020-17317-y. PubMed PMID: 32632160; 624 PubMed Central PMCID: PMCPMC7338506.

625 32. Wajnberg A, Mansour M, Leven E, Bouvier NM, Patel G, Firpo-Betancourt A, et al. Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an 626 627 observational study. Lancet Microbe. 2020;1(7):e283-e9. Epub 20200925. doi: 10.1016/S2666-628 5247(20)30120-8. PubMed PMID: 33015652; PubMed Central PMCID: PMCPMC7518831.

629 Ahmad A, Haq M, Rehman A, Haq NU. Anti-nucleocapsid IgG antibodies in SARS-CoV-2 33. 630 recovered health care workers: One year follow-up study. Int J Immunopathol Pharmacol. 2023;37:3946320231187744. doi: 10.1177/03946320231187744. PubMed PMID: 37394899; PubMed Central 631 632 PMCID: PMCPMC10328170.

633 Haveri A, Ekstrom N, Solastie A, Virta C, Osterlund P, Isosaari E, et al. Persistence of 34. 634 neutralizing antibodies a year after SARS-CoV-2 infection in humans. Eur J Immunol. 2021;51(12):3202-

13. Epub 20211008. doi: 10.1002/eji.202149535. PubMed PMID: 34580856; PubMed Central PMCID: 635 636 PMCPMC8646652.

637 35. Sun B, Feng Y, Mo X, Zheng P, Wang Q, Li P, et al. Kinetics of SARS-CoV-2 specific IgM and 638 COVID-19 patients. Emerg Microbes IgG responses in Infect. 2020;9(1):940-8. doi: 639 10.1080/22221751.2020.1762515. PubMed PMID: 32357808; PubMed Central PMCID: PMCPMC7273175. 640 36. SMHSA (Senegalese Ministry of Health and Social Action)2022 [Final report of the 2nd 641 seroprevalence survey of Covid-19 in Senegal, 2022.

642 37. Seck SM, Mbow M, Kane Y, Cisse MM, Faye G, Kama A, et al. Prevalence of SARS-CoV-2 643 antibodies in hemodialysis patients in Senegal: a multicenter cross-sectional study. BMC Nephrol. 644 2021;22(1):384. Epub 20211117. doi: 10.1186/s12882-021-02582-w. PubMed PMID: 34789170; PubMed 645 Central PMCID: PMCPMC8595275.

646 38. Ahouidi AD, Anderson M, Diedhiou CK, Dia A, Mbow M, Dia Y, et al. Seroprevalence of SARS-647 CoV-2 IgG antibodies in a healthcare setting during the first pandemic wave in Senegal. IJID Reg. 648 2022;2:96-8. Epub 20211224. doi: 10.1016/j.ijregi.2021.12.008. PubMed PMID: 35721431; PubMed Central 649 PMCID: PMCPMC8702669.

650 39. Talla C, Loucoubar C, Roka JL, Barry MA, Ndiaye S, Diarra M, et al. Seroprevalence of anti-651 SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between 652 October and November 2020. IJID Reg. 2022;3:117-25. Epub 20220305. doi: 10.1016/j.ijregi.2022.02.007. 653 PubMed PMID: 35720135; PubMed Central PMCID: PMCPMC8897837.

654 40. SMHSA (Senegalese Ministry of Health and Social Action)2023 [Final report of the 2nd 655 seroprevalence survey of Covid-19 in Senegal, 2023.

656 41. Diouara, A. A., et al. High Exposure to SARS-CoV-2 among Pregnant Women after the First 657 and Second Waves of COVID-19 in Senegal. Preprints. doi: 10.20944/preprints202310.1684.v1

658 42. Ndiaye AJS, Beye M, Lo G, Kacel I, Sow A, Leye N, et al. Genomic Epidemiology of SARS-CoV-2 659 in Urban Settings in Senegal. Viruses. 2023;15(6). Epub 20230524. doi: 10.3390/v15061233. PubMed 660 PMID: 37376533; PubMed Central PMCID: PMCPMC10302768.

661 43. Manirakiza A, Malaka C, Longo JD, Yambiyo BM, Diemer SH, Namsenei J, et al. Sero-662 prevalence of anti-SARS-CoV-2 antibodies among communities between July and August 2022 in 663 Bangui, Central African Republic. J Public Health Afr. 2023;14(8):2315. Epub 20230605. doi: 10.4081/jphia.2023.2315. PubMed PMID: 37753434; PubMed Central PMCID: PMCPMC10519115. 664

665 44. Akanmu S, Herrera BB, Chaplin B, Ogunsola S, Osibogun A, Onawoga F, et al. High SARS-CoV-666 2 seroprevalence in Lagos, Nigeria with robust antibody and cellular immune responses. J Clin Virol Plus. 2023;3(3):100156. Epub 20230624. doi: 10.1016/j.jcvp.2023.100156. PubMed PMID: 37388808; 667 PubMed Central PMCID: PMCPMC10289822. 668

Takahashi T, Wong P, Ellingson MK, Lucas C, Klein J, Israelow B, et al. Sex differences in 669 45. 670 immune responses to SARS-CoV-2 that underlie disease outcomes. medRxiv. 2020. Epub 20200626. doi: 671 10.1101/2020.06.06.20123414. PubMed PMID: 32577695; PubMed Central PMCID: PMCPMC7302304.

672 Zhang H, Tang Y, Tao J. Sex-Related Overactivation of NLRP3 Inflammasome Increases 46. 673 Lethality of the Male COVID-19 Patients. Front Mol Biosci. 2021;8:671363. Epub 20210604. doi: 674 10.3389/fmolb.2021.671363. PubMed PMID: 34150848; PubMed Central PMCID: PMCPMC8212049.

675 47. Zeng F, Dai C, Cai P, Wang J, Xu L, Li J, et al. A comparison study of SARS-CoV-2 IgG antibody 676 between male and female COVID-19 patients: A possible reason underlying different outcome between 677 sex. J Med Virol. 2020;92(10):2050-4. Epub 20200522. doi: 10.1002/jmv.25989. PubMed PMID: 32383183; 678 PubMed Central PMCID: PMCPMC7267228.

679 Felsenstein S, Hedrich CM. SARS-CoV-2 infections in children and young people. Clin Immunol. 48. 680 2020;220:108588. Epub 20200906. doi: 10.1016/j.clim.2020.108588. PubMed PMID: 32905851; PubMed 681 Central PMCID: PMCPMC7474910.

682 49. Backhaus I, Hermsen D, Timm J, Boege F, Lubke N, Degode T, et al. SARS-CoV-2 seroprevalence 683 and determinants of infection in young adults: a population-based seroepidemiological study. Public 684 Health. 2022;207:54-61. Epub 20220323. doi: 10.1016/j.puhe.2022.03.009. PubMed PMID: 35490440; 685 PubMed Central PMCID: PMCPMC8940565.

Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 Infection in Children. N Engl J 686 50. 687 Med. 2020;382(17):1663-5. Epub 20200318. doi: 10.1056/NEJMc2005073. PubMed PMID: 32187458; 688 PubMed Central PMCID: PMCPMC7121177.

689 Kearney M, Bornstein M, Fall M, Nianogo R, Glik D, Massey P. Cross-sectional study of COVID-51. 19 knowledge, beliefs and prevention behaviours among adults in Senegal. BMJ Open. 690 2022;12(5):e057914. Epub 20220526. doi: 10.1136/bmjopen-2021-057914. PubMed PMID: 35618332; 691 692 PubMed Central PMCID: PMCPMC9136694.

693 52. Jaureguizar J, Redondo I, Galende N, Ozamiz N. Factors related to compliance with the COVID-19 health regulations among young people. World J Psychiatry. 2021;11(12):1247-58. Epub 20211219. 694 doi: 10.5498/wjp.v11.i12.1247. PubMed PMID: 35070774; PubMed Central PMCID: PMCPMC8717041. 695

696 53. Kim JK, Crimmins EM. How does age affect personal and social reactions to COVID-19: Results 697 from the national Understanding America Study. PLoS One. 2020;15(11):e0241950. Epub 20201110. doi: 698 10.1371/journal.pone.0241950. PubMed PMID: 33170903; PubMed Central PMCID: PMCPMC7654776.

699 54. Yoo TK, Oh E, Kim HK, Ryu IH, Lee IS, Kim JS, et al. Deep learning-based smart speaker to 700 confirm surgical sites for cataract surgeries: A pilot study. PLoS One. 2020;15(4):e0231322. Epub 701 20200409. doi: 10.1371/journal.pone.0231322. PubMed PMID: 32271836; PubMed Central PMCID: 702 PMCPMC7144990.

703 55. Prakash N, Srivastava B, Singh S, Sharma S, Jain S. Effectiveness of social distancing 704 interventions in containing COVID-19 incidence: International evidence using Kalman filter. Econ Hum 705 Biol. 2022;44:101091. Epub 20211202. doi: 10.1016/j.ehb.2021.101091. PubMed PMID: 34894622; PubMed 706 Central PMCID: PMCPMC8638209.

- 707 Singhal S, Prakash N. A narrative inquiry into the meaning of career identity of Indian emerging 56. 708 adults amid Covid-19. Int J Educ Vocat Guid. 2023:1-26. Epub 20230316. doi: 10.1007/s10775-023-09590-2. 709 PubMed PMID: 37360271; PubMed Central PMCID: PMCPMC10019401.
- 710 57. Garg T, Votta CM, Prakash N, Deldin PJ. An investigation into the effectiveness of Mood Lifters 711 in the context of trauma exposure. Psychol Serv. 2023. Epub 20230824. doi: 10.1037/ser0000789. PubMed 712 PMID: 37616078.
- 713 Van Egeren D, Stoddard M, White LF, Hochberg NS, Rogers MS, Zetter B, et al. Vaccines Alone 58. 714 Cannot Slow the Evolution of SARS-CoV-2. Vaccines (Basel). 2023;11(4). Epub 20230416. doi: 715 10.3390/vaccines11040853. PubMed PMID: 37112765; PubMed Central PMCID: PMCPMC10143044.
- 716 Malik JA, Ahmed S, Mir A, Shinde M, Bender O, Alshammari F, et al. The SARS-CoV-2 59. 717 mutations versus vaccine effectiveness: New opportunities to new challenges. J Infect Public Health. 718 2022;15(2):228-40. Epub 20220105. doi: 10.1016/j.jiph.2021.12.014. PubMed PMID: 35042059; PubMed 719 Central PMCID: PMCPMC8730674.
- 720 Lopez Bernal J, Gower C, Andrews N, Public Health England Delta Variant Vaccine 60. 721 Effectiveness Study G. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. Reply. 722 N Engl J Med. 2021;385(25):e92. Epub 20211110. doi: 10.1056/NEJMc2113090. PubMed PMID: 34758250.
- Cohen JI, Burbelo PD. Reinfection With SARS-CoV-2: Implications for Vaccines. Clin Infect Dis. 723 61. 724 2021;73(11):e4223-e8. doi: 10.1093/cid/ciaa1866. PubMed PMID: 33338197; PubMed Central PMCID: 725 PMCPMC7799323.
- 726 62. Wolff D, Nee S, Hickey NS, Marschollek M. Risk factors for Covid-19 severity and fatality: a 727 structured literature review. Infection. 2021;49(1):15-28. Epub 20200828. doi: 10.1007/s15010-020-01509-728 1. PubMed PMID: 32860214; PubMed Central PMCID: PMCPMC7453858.
- 729 63. Aburto S, Cisterna M, Acuna J, Ruiz C, Viscardi S, Marquez JL, et al. Obesity as a Risk Factor 730 for Severe COVID-19 in Hospitalized Patients: Epidemiology and Potential Mechanisms. Healthcare 731 (Basel). 2022;10(10). Epub 20220922. doi: 10.3390/healthcare10101838. PubMed PMID: 36292285; 732 PubMed Central PMCID: PMCPMC9601462.
- 733 Mackey K, Ayers CK, Kondo KK, Saha S, Advani SM, Young S, et al. Racial and Ethnic 64. 734 Disparities in COVID-19-Related Infections, Hospitalizations, and Deaths : A Systematic Review. Ann 735 Intern Med. 2021;174(3):362-73. Epub 20201201. doi: 10.7326/M20-6306. PubMed PMID: 33253040;
- 736 PubMed Central PMCID: PMCPMC7772883.

Carethers JM. Insights into disparities observed with COVID-19. J Intern Med. 2021;289(4):463-737 65. 73. Epub 20201206. doi: 10.1111/joim.13199. PubMed PMID: 33164230; PubMed Central PMCID: 738

PMCPMC9325576. 739

740 Fogh K, Eriksen ARR, Hasselbalch RB, Kristensen ES, Bundgaard H, Nielsen SD, et al. 66. 741 Seroprevalence of SARS-CoV-2 antibodies in social housing areas in Denmark. BMC Infect Dis. 742 2022;22(1):143. Epub 20220210. doi: 10.1186/s12879-022-07102-1. PubMed PMID: 35144550; PubMed 743 Central PMCID: PMCPMC8830972.

744 Megasari NLA, Yamani LN, Juniastuti J, Lusida MI, Mori Y. Seroprevalence of SARS-CoV-2 67.

745 anti-spike IgG antibody among COVID-19 vaccinated individuals residing in Surabaya, East Java,

Indonesia. PeerJ. 2023;11:e16142. Epub 20230925. doi: 10.7717/peerj.16142. PubMed PMID: 37780375; 746

747 PubMed Central PMCID: PMCPMC10538276.

748




Figure 1. Flowchart of participants' enrolment for the anti-SARS-CoV-2 antibody seroprevalence study in Superior Polytechnic School

	Variable	Value, N (%)
	Overall	637 (100)
	Age (years)	
	Mean	23.20
	Median	21
	Range	18 - 63
	Age group (years)	
	[18-25]	546 (85.71)
	(25-35]	38 (5.96)
	(35-45]	26 (4.08)
	(45-55]	12 (1.88)
	(55-65]	6 (0.94)
	Gender	
	Female	395 (62)
rint doi: https://doi.org/10.1101/20. ch was not certified by peer rev It is made a	2VDa 2C 24301904; this version posted January 30, 2024. The cop iew) is the author/funder, who has granted medRxiv a license to dis nerpetuity. available under a CC BY 4.0 International license .	. ,
	Students	563 (88.38)
	Professors	22 (3.45)
	TASO	52 (8.16)
	Level of education	. ,
	Bachelor degree	450 (70.64)
-	Master degree	117 (18.36)
-	PhD	20 (3.14)
	others	18 (2.82)
	Nationality	. ,
	Senegalese	603 (94.66)
	Others t	32 (5.03)
	Ethnic groups	· · ·
	Wolof	153 (24.02)
-	Fula	139 (21.82)
-	Serer	79 (12.40)
-	Jola	16 (2.50)
-	Malinke	17 (2.67)
-	Soninke	9 (1.41)
-	Mauri	7 (1.1)
-	Others t	18 (2.82)
-	Accommodation type	()
	Halls of residence	138 (21.67)
-	Family home	479 (75.19)
	Family members	2.7 (10127)
	Family members	
-	1-2	37 (5.81)
		0, (0,01)

Table I: Baseline characteristics of the study population

1-2	37 (5.81)
3-5	247 (38.77)
6-8	188 (29.51)
9 or plus	74 (11.61)
Matrimonial status	
Single	558 (87.60)
Married	60 (9.42)
Divorced	2 (0.31)
Smoker	
Yes	10 (1.88)
No	538 (84.30)
Stopped > 1 year	10 (1.41)

	Alcohol consumer	
	Yes	21 (3.62)
	No	554 (86.81)
	Stopped > 1 year	3 (0.31)
	BMI Categorized	
	Underweight	69 (10.83)
	Normal weight	240 (37.68)
	Overweight /Obesity	53 (8.32)
	Blood Group	
	A-	9 (1.41)
	A+	140 (21.98)
	AB-	1 (0.15)
	AB+	25 (3.92)
	B-	5 (0.78)
	B+	102 (16.01)
	0-	24 (3.77)
nedRxiv preprint doi: https://doi.org/10.1107 preprint (which was not certified by peer	1/2024 01.28.24301904; this version posted January 30, 2024. T reveal is the author/funder, who has granted medRxiv a licens	The copyright holder for this se to display the preprint in
It is ma	perpetuity. de avaiale/uniter allo-by a conternational license .	
	Yes	221 (35.01)
	No	365 (57.46)
	Prefer not to say	51 (7.54)

N number; BMI Body Mass Indice; TASO technicians, administrative and service officers

+ For nationality and ethnic group, others correspond to others of African nationality or ethnic group with very small numbers (maximum 5)




Figure 2: Compliance with Preventive measures recommended by authorities

Table II: Distribution of SARS-CoV-2 Ig M and G seropositive and seronegative
individuals among the 637 participants enrolled.

Variable	Saranagativa	IgM Seropositive <i>p-value</i>		Saranagativa	IgG Saranasitiwa	p-valu
	Seronegative N (%)	N (%)	p-vuite	Seronegative N (%)	Seropositive N (%)	p-oun
Overall	593 (93.09)	44 (6.91)		51 (8)	576 (92)	
Age (years)						
Mean	23.06	25.16		22.4	23.28	
Median	21	21		21	21	
Range	18 - 63	18 - 59		18 - 47	18 - 63	
Age group			<0,001*			0,98
[18-25]	516 (94.50)	30 (5.5)		53 (9.7)	493 (92.3)	
(25-35]	29 (76.31)	9 (23.69)		4 (10.53)	34 (89.47)	
(35-45]	24 (92.31)	2 (7.69)		2 (7.69)	24 (92.31)	
	12 (100)				11 (91.67)	
45-55 print doi: https://doi.org/10.1101/2024. https://doi.org/10.1101/2024.	01.28.24301904; this version) is the author/funder, who have a tributed and the second se	posted January 30, 2024. as granted medRxiv a licer	The copyright ho use to display the	preprintin	6 (100)	
, ,	perpetuity. ilable under a CC-BY 4.0 Inte		0.16			0.89
Female	373 (94.43)	22 (5.57)		37 (9.36)	358 (90.63)	
Male	213 (90.64)	22 (9.36)		24 (10.21)	211 (89.79)	
Occupation			0.15	(,		0.71
Students	528 (93.78)	35 (6.22)	0120	55 (9.77)	508 (90.23)	
Professors	19 (86.36)	3 (13.64)		1 (9.61)	21 (90.38)	
TASO	46 (88.46)	6 (11.54)		5 (4.54)	47 (95.45)	
Level of education	10 (00.10)	0(11.04)	0.18	0 (101)	1 (55.15)	0.45
Bachelor degree	423 (94)	27 (6)	0.10	46 (10.22)	404 (89.78)	0110
Master degree	105 (84.74)	12 (10.26)		12 (10.25)	105 (89.75)	
PhD	17 (85)	3 (15)		1 (5)	19 (95)	
others	16 (88.89)	2 (11.11)		0 (0)	18 (100)	
Nationality	10 (00.05)	2(11.11)	0.29	0(0)	10 (100)	0.30
Senegalese	565 (93.39)	40 (6.61)	0.27	56 (9.26)	549 (90.74)	0.00
Others t	26 (86.67)	4 (13.33)		5 (16.67)	25 (83.33)	
Ethnic groups	20 (00.07)	4(10.00)	0.25	5 (10.07)	25 (05.55)	0.17
Wolof	145 (94.77)	8 (5.23)	0.20	14 (9.15)	139 (90.85)	0.17
Fula	128 (92.09)	11 (7.91)		11 (7.91)	128 (92.09)	
Serer	72 (91.14)	7 (8.86)		8 (10.13)	71 (89.87)	
Jola	14 (87.50)	2 (12.50)		0 (0)	16 (100)	
Malinke	16 (94.12)	1 (5.88)		3 (17.65)	14 (82.35)	
Soninke	9 (100)	0 (0)		3 (33.33)	6 (66.67)	
Mauri	7 (100)	0 (0)		0 (0)	7 (100)	
Others t	14 (77.78)	4 (22.22)		2 (11.12)	16 (88.88)	
Accommodation type	14(7.70)	4 (22.22)	0.73	2(11.12)	10 (00.00)	0.76
Halls of residence	127 (92.03)	11 (7 07)	0.75	12 (8.69)	126 (91.31)	0.70
Family home	447 (93.32)	11 (7.97) 32 (6.68)		48 (10.02)	431 (89.98)	
Family members	447 (55.52)	52 (0.00)	0.54	40 (10.02)	451 (69.90)	0.32
1-2	36 (97.30)	1 (2 70)	0.54	2 (5.40)	25 (04 60)	0.52
3-5		1 (2.70)			35 (94.60)	
6-8	227 (91.90)	20 (8.10)		29 (11.75)	218 (88.25)	
	176 (93.62)	12 (6.38)		20 (10.64)	168 (89.36)	
9 or plus	78 (90.70)	8 (9.30)	0.062	5 (5.81)	81 (94.19)	0.52
Matrimonial Status	E24 (02 0)	24 (6 1)	0.062	E4 (0 (9)	504 (00 22)	0.53
Single	524 (93.9)	34 (6.1)		54 (9.68)	504 (90.32)	
Married	51 (85)	9 (15)		7 (11.67)	53 (88.33)	-
Divorced	2 (100)	0 (0)	0.00	0 (0)	2 (100)	0.17
Smoker	10 (100)	0.(0)	0.08	0.00	14 (100)	0.16
Yes	10 (100)	0 (0)		0 (0)	14 (100)	
No	503 (93.49)	35 (6.51)		57 (9.69)	531 (90.31)	
Stopped > 1 year	8 (80)	2 (20)	0.10	0 (0)	10 (100)	0.000
Alcohol consumer			0.12			0.038
Yes	19 (90.48)	2 (9.52)		1 (4.76)	20 (95.24)	

No	516 (93.14)	38 (6.86)		51 (9.20)	503 (90.80)	
Stopped > 1 year	3 (100)	0 (0)		1 (33.34)	2 (66.66)	
BMI Categorized			0.089			0.55
Underweight	67 (97.10)	2 (2.90)		6 (8.70)	63 (91.30)	
Normal weight	224 (93.33)	16 (6.67)		28 (11.67)	212 (88.33)	
Overweight /Obesity	46 (86.79)	7 (11.36)		8 (15.09)	45 (84.91)	
Blood Group			0.95			0.094
A-	8 (88.89)	1 (11.11)		1 (11.11)	8 (88.89)	
A+	131 (93.57)	9 (6.43)		14 (10)	126 (90)	
AB-	1 (100)	0 (0)		1 (100)	0 (0)	
AB+	24 (96)	1 (4)		3 (12)	22 (88)	
B-	4 (80)	1 (20)		0 (0)	5 (100)	
B+	94 (92.16)	8 (7.84)		7 (6.86)	95 (93.14)	
0-	22 (91.67)	2 (8.33)		1 (4.17)	23 (95.83)	
O+	279 (93)	21 (7)		29 (9.67)	271 (90.33)	
COVID-19 Vaccination			0.624			< 0.0001
Yes	203 (91.85)	18 (8.15)		7 (3.17)	214 (96.83)	
No eprint doi: https://doi.org/10.1101/2024.01	340 (95.15)	25 (6.85)		49 (13.42)	316 (86.58)	
eprint doi: https://doi.org/10.1101/2024.01	1.28.24301904; this version	on posted January 30, 20	24. The copyright r	loider for this	46 (00.0)	

medRxiv preprint doi: https://doi.org/10.1101/2024.01.28.24301904; this version posted January '30, 2024. The copyright holder for this preprint (which crashes the preprint (which crashes the preprint (which crashes the preprint (which crashes the preprint (bits)) is the automy function of the preprint (which crashes the preprint (bits)) is the automy function of the preprint (bits) and the preprint (bits) and the preprint (bits) are preprint (bits) and the preprint (bits) are preprint (bits) and the preprint (bits) are preprint (bits) are

Table III. Distribution of Sars-Cov-2 Ig M and G seropositive and seronegative according to preventive measures

	IgM			IgG			
	Seronegative n (%)	Seropositive n (%)	p- value	Seronegative n (%)	Seropositive n (%)	p- valu	
Wearing masks			0.17			0.73	
Always/Often	183 (91.04)	18 (8.96)		19 (9.45)	182 (90.55)		
Sometimes/Rarely	355 (93.42)	25 (6.58)		38 (10)	342 (90)		
Never	30 (100)	0 (0)		4 (13.33)	26 (86.67)		
Kept a physical distance of 2 m			0.35			0.33	
Always/Often	110 (94.83)	6 (5.17)		8 (6.90)	108 (93.10)		
Sometimes/Rarely	277 (91.42)	26 (8.58)		31 (10.23)	272 (89.77)		
Never	161 (94.15)	10 (5.85)		21 (12.28)	150 (87.72)		
Wash hands with print doi: https://doi.org/10.1101/2024. https://doi.org/10.1101/2024. or with soap altict ^{hade} ava water	nernetuity		0.105 24. The copyri license to displ	ght holder for this ay the preprint in		0.599	
Always/Often	451 (93.96)	29 (6.04)		51 (10.62)	429 (89.38)		
Sometimes/Rarely	108 (88.52)	14 (11.48)		10 (8.20)	112 (91.80)		
Never	4 (100)	0 (0)		0 (0)	4 (100)		
Number of visits received in the last 15 days			0.583			0.971	
0-2	205 (93.61)	14 (6.39)		23 (10.50)	196 (89.50)		
3-8	188 (92.16)	16 (7.84)		21 (10.29)	183 (89.71)		
≥9	146 (94.80)	8 (5.20)		15 (9.74)	139 (90.26)		
Number of visits made in the last 15 days			0.008*			0.946	
0-2	373 (94.20)	23 (5.81)		41 (10.35)	355 (89.65)		
3-8	109 (87.20)	16 (12.80)		12 (9.60)	113 (90.40)		
≥9	73 (97.33)	2 (2.67)		7 (9.33)	68 (90.67)		
Public transport use per day over the last 15 days			0.878			0.668	
0-2	419 (92.9)	32 (7.1)		44 (9.75)	407 (90.25)		
3-5	105 (92.92)	8 (7.1)		14 (12.39)	99 (87.61)		
≥9	33 (91.67)	3 (8.33)		3 (8.33)	33 (91.67)		
Participation in a social event in the last 15 days			0.589			0.289	
0-2	423 (92.76)	33 (7.24)		51 (11.18)	405 (88.82)		
3-8	79 (90.80)	8 (9.20)		5 (5.75)	82 (94.25)		
≥9	44 (95.65)	2 (4.35)		4 (8.70)	42 (91.30)		

Significant values are in bold.

Table IV: Multiple logistic regression of sociodemographical risk factors affecting seropositivity

	IgM				IgG			
Variable	Univariate OR (95% CI)	p- value	Multivariate OR (95% CI)	p- value	Univariate OR (95% CI)	p- value	Multivariate OR (95% CI)	p- value
Age	1.034 [0.99 - 1.06]	0.055	0.971 [0,74 -1,21]	0,808	1.023 [0.98 – 1.081]	0.345	0.974 [0.89 – 1.071]	0.573
Gender	1.75 [0.943 - 3.25]	0.073	0.776 [0,10 – 4.6]	0.791	0.906 [0.53 - 1.578]	0.728	0.913 [0.52 - 1.62	0.757
Occupation	1.652 [0.92 – 2.72]	0.065	1.345[0,06 – 22.03]	0.834	1.26 [0.69 – 2.75]	0.508	2.545 [0.60 – 15.33]	0.250
Level of education	1.526 [0.91 – 2.47]	0.095	1.709 [0.31 – 9.47]	0.532	0.973 [0.61 – 1.61]	0.911	0.917 [0.48 – 1.73]	0.790
Nationality			0.074 [0.003 – 2.21]	0.083	1.96 [0.64 - 4.93]	0.186	2.286 [0.49 – 7.82]	0.225
Ethnic groups	0.985 [0.86 – 1.13]	0.826	0.723 [0.49 – 0.96] s version posted January 30, 20	0.046 *	0.95 [0.84 - 1.07]	0.426	0.967 [0.85 – 1.095]	0.6
residence	cert(fied by peer review) is	s the author/funde perpetuit	er, who has granted medRxiv a	024. The copyrigi license to display	thele999960t[0.80 – 1.27]	0.992	0.981 [0.74 – 1.32]	0.894
Accommodatio n type	1.21 [0.57 – 2.40]	0.60	4.209 [0.91 – 21.62)	0.067	1.17 [0.62 - 2.37]	0.643	0.924 [0.41 - 2.23]	0.854
Family members	1.133 [0.77 – 1.66]	0.522	1.849 [0.78 – 4.78]	0.175	1.138 [0.81 – 1.6]	0.452	1.234 [0.83 – 1.85]	0.296
Maritus status	2.399 [1.08 – 4.87]	0.021 *	4.44 [0.28 – 54.32]	0.235	1.02 [0.47 – 2.68]	0.956	1.135 [0.43 – 3.95]	0.818
Smoking	1.004 [0.21 – 2.48]	0.995	2.897 [0.087 – 36.8]	0.457				
Alcohol	1.064 [0.18 - 3.17]	0.926	2.06 [0.066 – 30.84}	0.622	0.835 [0.32 – 3.25]	0.747		
BMI Categorized	2.015 [1.12 – 3.56]	0.016 *	1.215 [0.39 – 3.73]	0.729	0.785 [0.49 – 1.29]	0.329	0.718 [0.43 – 1.21]	0.206
Blood Group	1.011 [0.89 – 1.152]	0.861	1.049 [0.786 – 1.47]	0.235	1.023 [0.91 – 1.14]	0.679	0.988 [0.86 – 1.24]	0.842
Vaccination Status	1.206 [0.63 – 2.25]	0.560	0.428 [0.08 – 1.89]	0.285	4.741 [2.25 – 11.65]	<0.00 1 *	2.714 [0.59 – 48.48]	0.325

OR odds ratio. Signifcant values are in bold.

Table V: Multiple logistic regression of preventive measures affecting seropositivity

		IgM		IgG	
	Variable	Univariate OR (95% CI)	p- value	Univariate OR (95% CI)	p- value
	Wearing masks	0.796 [0,5893 - 1,073]	0.134	0.966 [0.74 – 1.25]	0.793
	Failure to respect the 2m distance	0.980 [0,7380 - 1,278]	0.886	1.229 [0.96 – 1.59]	0.108
dRxiv preprint do ∍print (which wa	Number of visits received in i: the /lest gl4. day2024.01.28.24301904; this is not certified by peer review) is the author/funde Number of visits made parpetuity It is made available under a CC-BY the last 14 days	r, who has granted medRxiv a licens	0.404 The copyright holder se to display the prep	1.002 [0.82 – 1.23] for this print in	0.984
	Wash hands with hydroalcoholic	0.854 [0.62 – 1.17]	0.327	0.891 [0.68 – 1.17]	0.405
	Public transport use per day over the last 15 days	1.043 [0.75 – 1.40]	0.793	1.072 [0.82 – 1.441]	0.630
	Participation in a social event in the last 15 days	0.952 [0.71 – 1.24]	0.734	1.094 [0.86 – 1.420]	0.473